3 results
The primary objective is to demonstrate the efficacy using 2 co-primary endpoints (as measured by thechanges from baseline to the end of Week 16 in Western Ontario and McMaster UniversityOsteoarthritis Index [WOMAC] pain and physical function…
The purpose of this study is to compare the good and bad effects of bermekimab to the good and bad effects of adalimumab and/or placebo. Adalimumab is a drug already used to treat moderate to severe hidradenitis suppurativa (HS).
TEMPO will directly compare i) conventional 2-step reduction with ii) gradual tapering in patients with remitted MDD who use either the antidepressant paroxetine (PAR) or venlafaxine (VLX). We will evaluate the number of patients that can…